[Management of advanced stage chronic myeloid leukemia]

Rinsho Ketsueki. 2014 Oct;55(10):1860-9.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Allografts
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Benzamides / administration & dosage
  • Benzamides / therapeutic use*
  • Dasatinib
  • Disease Progression
  • Drug Design
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Fusion Proteins, bcr-abl / genetics
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Imatinib Mesylate
  • Imidazoles / administration & dosage
  • Imidazoles / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Molecular Targeted Therapy*
  • Neoplasm Staging
  • Piperazines / administration & dosage
  • Piperazines / therapeutic use*
  • Point Mutation
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridazines / administration & dosage
  • Pyridazines / therapeutic use
  • Pyrimidines / administration & dosage
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Thiazoles / administration & dosage
  • Thiazoles / therapeutic use

Substances

  • Benzamides
  • Imidazoles
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyridazines
  • Pyrimidines
  • Thiazoles
  • ponatinib
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • nilotinib
  • Dasatinib